Chromosomal microarray (CMA) testing provides genetic analysis for a large number of serious genetic disorders and has applications in hereditary genetics and oncology. By analyzing both copy number and SNP probes, we can assess deletions and duplications across the genome, determine their precise breakpoints and gene content, and detect regions of homozygosity.  CMA testing generates large amounts of complex data that require a high level of expertise to accurately assess and classify. Our laboratory directors review thousands of CMA tests each year and are actively involved in the field of genomics, helping create testing standards and shape practice guidelines.


A Test in Focus Series – Chromosomal Microarray, Tumor (Test ID: CMAPT)

CMA testing can be used in several areas of oncology. Three Mayo Clinic physicians discuss how this testing is used for different clinical applications.


CMA Testing for Gliomas

Robert Jenkins, M.D., Ph.D., a pathologist and cancer geneticist at Mayo Clinic, provides an overview of CMA testing and discusses when this testing should be used for patients with gliomas. He also covers other available testing methods and discusses how the results can impact patient care.


CMA Testing for Melanoma

Katherine Geiersbach, M.D., a pathologist in the Genomics Division at Mayo Clinic, provides an overview of CMA testing and discusses when this testing should be used for melanoma patients. She also covers other available testing methods and discusses how the results of CMA can impact patient care in the setting of a possible diagnosis of melanoma.

Testing

Additional Resources

Neuro-Oncology Brochure

For more information on how to order CMA at your institution, fill out the form below.

Alyssa Frank

Alyssa Frank

Alyssa Frank is a Marketing Segment Manager at Mayo Clinic Laboratories. She leads marketing strategies for product management and specialty testing. Alyssa has worked at Mayo Clinic since 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *